Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib-MedSci.cn

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Cortes, JE; Saikia, T; Kim, DW; Alvarado, Y; Nicolini, FE; Khattry, N; Rathnam, K; Apperley, J; Deininger, MW; de Lavallade, H; Charbonnier, A; Granacher, N; Gambacorti-Passerini, C; Lucchesi, A; Mauro, MJ; Verhoef, G; Vandenberghe, P; Whiteley, AR; Apte, S; Yao, SL; Kothekar, M; Sreenivasan, J; Bimba, HV; Chimote, G

BLOOD, 2020; 136 ():

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

科室

工具

服务